PTO- 1478
`
`Approved for use through 09/30/2021. OMB 0651-0009
`
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number
`
`Trademark/Service Mark Application, Principal Register
`
`Serial Number: 97009108
`Filing Date: 09/02/2021
`
`The table below presents the data as entered.
`
`Input Field
`
`Entered
`
`SERIAL NUMBER
`
`MARK INFORMATION
`
`*MARK
`
`STANDARD CHARACTERS
`
`USPTO-GENERATED IMAGE
`
`LITERAL ELEMENT
`
`MARK STATEMENT
`
`REGISTER
`
`APPLICANT INFORMATION
`
`*OWNER OF MARK
`
`*MAILING ADDRESS
`
`*CITY
`
`*STATE
`(Required for U.S. applicants)
`
`*COUNTRY/REGION/JURISDICTION/U.S. TERRITORY
`
`*ZIP/POSTAL CODE
`(Required for U.S. and certain international addresses)
`
`*EMAIL ADDRESS
`
`LEGAL ENTITY INFORMATION
`
`TYPE
`
`97009108
`
`ORYZA PHARMACEUTICALS INC.
`
`YES
`
`YES
`
`ORYZA PHARMACEUTICALS INC.
`
`The mark consists of standard characters, without claim to any
`particular font style, size, or color.
`
`Principal
`
`Oryza Pharmaceuticals, Inc.
`
`4117 NW 124th Ave
`
`Coral Springs
`
`Florida
`
`United States
`
`33065
`
`XXXX
`
`corporation
`
`STATE/COUNTRY/REGION/JURISDICTION/U.S. TERRITORY OF
`INCORPORATION
`
`Florida
`
`GOODS AND/OR SERVICES AND BASIS INFORMATION
`
`INTERNATIONAL CLASS
`
`005 
`
`*IDENTIFICATION
`
`FILING BASIS
`
`       FIRST USE ANYWHERE DATE
`
`       FIRST USE IN COMMERCE DATE
`
`       SPECIMEN FILE NAME(S)
`
`Pharmaceutical preparations for curing and alleviating various
`illnesses
`
`SECTION 1(a)
`
`At least as early as 02/01/2021
`
`At least as early as 02/01/2021
`
`\\TICRS\EXPORT18\IMAGEOUT
`18\970\091\97009108\xml1 \ APP0003.JPG
`
`

`

`       SPECIMEN DESCRIPTION
`
`        WEBPAGE URL
`
`        WEBPAGE DATE OF ACCESS
`
`INTERNATIONAL CLASS
`
`*IDENTIFICATION
`
`FILING BASIS
`
`INTERNATIONAL CLASS
`
`*IDENTIFICATION
`
`FILING BASIS
`
`       FIRST USE ANYWHERE DATE
`
`       FIRST USE IN COMMERCE DATE
`
`       SPECIMEN FILE NAME(S)
`
`       ORIGINAL PDF FILE
`
`       CONVERTED PDF FILE(S)
`       (5 pages)
`
`Picture of box for the preparations
`
`None Provided
`
`None Provided
`
`005 
`
`Nutraceuticals for the treatment of various dietary
`supplemental needs; Nutraceuticals for use as a dietary
`supplement
`
`SECTION 1(b)
`
`041 
`
`Pharmaceutical research and development; Development of
`pharmaceutical preparations and medicines
`
`SECTION 1(a)
`
`At least as early as 03/15/2016
`
`At least as early as 03/15/2016
`
`SPE0-6412422226-202109021 43555145139_._4942-102SPE
`C41.pdf
`
`\\TICRS\EXPORT18\IMAGEOUT
`18\970\091\97009108\xml1\ APP0004.JPG
`
`\\TICRS\EXPORT18\IMAGEOUT
`18\970\091\97009108\xml1\ APP0005.JPG
`
`\\TICRS\EXPORT18\IMAGEOUT
`18\970\091\97009108\xml1\ APP0006.JPG
`
`\\TICRS\EXPORT18\IMAGEOUT
`18\970\091\97009108\xml1\ APP0007.JPG
`
`\\TICRS\EXPORT18\IMAGEOUT
`18\970\091\97009108\xml1\ APP0008.JPG
`
`       SPECIMEN DESCRIPTION
`
`Pages from Applicant's website showing services offered
`
`        WEBPAGE URL
`
`        WEBPAGE DATE OF ACCESS
`
`ATTORNEY INFORMATION
`
`NAME
`
`ATTORNEY DOCKET NUMBER
`
`ATTORNEY BAR MEMBERSHIP NUMBER
`
`YEAR OF ADMISSION
`
`U.S. STATE/ COMMONWEALTH/ TERRITORY
`
`FIRM NAME
`
`INTERNAL ADDRESS
`
`STREET
`
`CITY
`
`http://oryzapharma.com/about-us.html and
`http://oryzapharma.com/products.html
`
`09/02/2021
`
`E. Anthony Figg
`
`4942-102
`
`XXX
`
`XXXX
`
`XX
`
`Rothwell, Figg, Ernst & Manbeck, PC
`
`Suite 800
`
`607 14th Street NW
`
`Washington
`
`       
`       
`       
`       
`

`

`STATE
`
`COUNTRY/REGION/JURISDICTION/U.S. TERRITORY
`
`ZIP/POSTAL CODE
`
`PHONE
`
`FAX
`
`EMAIL ADDRESS
`
`District of Columbia
`
`United States
`
`20005
`
`202-783-6040
`
`202-783-6031
`
`PTO-TM-Email@rfem.com
`
`OTHER APPOINTED ATTORNEY
`
`Leo M. Loughlin, Davide F. Schiavetti
`
`CORRESPONDENCE INFORMATION
`
`NAME
`
`E. Anthony Figg
`
`PRIMARY EMAIL ADDRESS FOR CORRESPONDENCE
`
`PTO-TM-Email@rfem.com
`
`SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES)
`
`NOT PROVIDED
`
`FEE INFORMATION
`
`APPLICATION FILING OPTION
`
`NUMBER OF CLASSES
`
`APPLICATION FOR REGISTRATION PER CLASS
`
`*TOTAL FEES DUE
`
`*TOTAL FEES PAID
`
`SIGNATURE INFORMATION
`
`SIGNATURE
`
`SIGNATORY'S NAME
`
`SIGNATORY'S POSITION
`
`SIGNATORY'S PHONE NUMBER
`
`DATE SIGNED
`
`SIGNATURE METHOD
`
`TEAS Standard
`
`2
`
`350
`
`700
`
`700
`
`/Leo M. Loughlin/
`
`Leo M. Loughlin
`
`Attorney of record, DC bar member
`
`202-783-6040
`
`09/02/2021
`
`Sent to third party for signature
`
`

`

`PTO- 1478
`
`Approved for use through 09/30/2021. OMB 0651-0009
`
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number
`
`Trademark/Service Mark Application, Principal Register
`
`To the Commissioner for Trademarks:
`
`Serial Number: 97009108
`Filing Date: 09/02/2021
`
`MARK: ORYZA PHARMACEUTICALS INC. (Standard Characters, see mark)
`The literal element of the mark consists of ORYZA PHARMACEUTICALS INC.. The mark consists of standard characters, without claim to
`any particular font style, size, or color.
`The applicant, Oryza Pharmaceuticals, Inc., a corporation of Florida, having an address of
`      4117 NW 124th Ave
`      Coral Springs, Florida 33065
`      United States
`      XXXX
`
`requests registration of the trademark/service mark identified above in the United States Patent and Trademark Office on the Principal Register
`established by the Act of July 5, 1946 (15 U.S.C. Section 1051 et seq.), as amended, for the following:
`
`International Class 005:  Pharmaceutical preparations for curing and alleviating various illnesses
`
`In International Class 005, the mark was first used by the applicant or the applicant's related company or licensee or predecessor in interest at
`least as early as 02/01/2021, and first used in commerce at least as early as 02/01/2021, and is now in use in such commerce. The applicant is
`submitting one(or more) specimen(s) showing the mark as used in commerce on or in connection with any item in the class of listed
`goods/services, consisting of a(n) Picture of box for the preparations.
`Specimen File1
`Webpage URL: None Provided
`Webpage Date of Access: None Provided
`
`International Class 005:  Nutraceuticals for the treatment of various dietary supplemental needs; Nutraceuticals for use as a dietary supplement
`Intent to Use: The applicant has a bona fide intention, and is entitled, to use the mark in commerce on or in connection with the identified
`goods/services.
`
`International Class 041:  Pharmaceutical research and development; Development of pharmaceutical preparations and medicines
`
`In International Class 041, the mark was first used by the applicant or the applicant's related company or licensee or predecessor in interest at
`least as early as 03/15/2016, and first used in commerce at least as early as 03/15/2016, and is now in use in such commerce. The applicant is
`submitting one(or more) specimen(s) showing the mark as used in commerce on or in connection with any item in the class of listed
`goods/services, consisting of a(n) Pages from Applicant's website showing services offered.
`
`Original PDF file:
`SPE0-6412422226-202109021 43555145139_._4942-102SPE C41.pdf
`Converted PDF file(s) (5 pages)
`Specimen File1
`Specimen File2
`Specimen File3
`Specimen File4
`Specimen File5
`Webpage URL: http://oryzapharma.com/about-us.html and http://oryzapharma.com/products.html
`Webpage Date of Access: 09/02/2021
`
`The owner's/holder's proposed attorney information: E. Anthony Figg. Other appointed attorneys are Leo M. Loughlin, Davide F. Schiavetti. E.
`Anthony Figg of Rothwell, Figg, Ernst & Manbeck, PC, is a member of the XX bar, admitted to the bar in XXXX, bar membership no. XXX,
`and the attorney(s) is located at
`
` 
`

`

`      Suite 800
`      607 14th Street NW
`      Washington, District of Columbia 20005
`      United States
`      202-783-6040(phone)
`      202-783-6031(fax)
`      PTO-TM-Email@rfem.com
`The docket/reference number is 4942-102.
`E. Anthony Figg submitted the following statement: The attorney of record is an active member in good standing of the bar of the highest court
`of a U.S. state, the District of Columbia, or any U.S. Commonwealth or territory.
`The applicant's current Correspondence Information:
`      E. Anthony Figg
`       PRIMARY EMAIL FOR CORRESPONDENCE: PTO-TM-Email@rfem.com       SECONDARY EMAIL ADDRESS(ES) (COURTESY
`COPIES): NOT PROVIDED
`
`Requirement for Email and Electronic Filing: I understand that a valid email address must be maintained by the applicant owner/holder and
`the applicant owner's/holder's attorney, if appointed, and that all official trademark correspondence must be submitted via the Trademark
`Electronic Application System (TEAS).
`A fee payment in the amount of $700 has been submitted with the application, representing payment for 2 class(es).
`
`Basis:
`If the applicant is filing the application based on use in commerce under 15 U.S.C. § 1051(a):
`
`Declaration
`
`The signatory believes that the applicant is the owner of the trademark/service mark sought to be registered;
`The mark is in use in commerce and was in use in commerce as of the filing date of the application on or in connection with the
`goods/services in the application;
`The specimen(s) shows the mark as used on or in connection with the goods/services in the application and was used on or in
`connection with the goods/services in the application as of the application filing date; and
`To the best of the signatory's knowledge and belief, the facts recited in the application are accurate.
`
`And/Or
`If the applicant is filing the application based on an intent to use the mark in commerce under 15 U.S.C. § 1051(b), § 1126(d),
`and/or § 1126(e):
`
`The signatory believes that the applicant is entitled to use the mark in commerce;
`The applicant has a bona fide intention to use the mark in commerce and had a bona fide intention to use the mark in commerce as
`of the application filing date on or in connection with the goods/services in the application; and
`To the best of the signatory's knowledge and belief, the facts recited in the application are accurate.
`
`To the best of the signatory's knowledge and belief, no other persons, except, if applicable, concurrent users, have the right to use the
`mark in commerce, either in the identical form or in such near resemblance as to be likely, when used on or in connection with the
`goods/services of such other persons, to cause confusion or mistake, or to deceive.
`
`To the best of the signatory's knowledge, information, and belief, formed after an inquiry reasonable under the circumstances, the
`allegations and other factual contentions made above have evidentiary support.
`
`The signatory being warned that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. §
`1001, and that such willful false statements and the like may jeopardize the validity of the application or submission or any registration
`resulting therefrom, declares that all statements made of his/her own knowledge are true and all statements made on information and
`belief are believed to be true.
`Declaration Signature
`
`Signature: /Leo M. Loughlin/   Date: 09/02/2021
`Signatory's Name: Leo M. Loughlin
`Signatory's Position: Attorney of record, DC bar member
`Signatory's Phone Number: 202-783-6040
`Signature method: Sent to third party for signature
`Payment Sale Number: 97009108
`Payment Accounting Date: 09/02/2021
`
`

`

`Serial Number: 97009108
`Internet Transmission Date: Thu Sep 02 16:29:43 ET 2021
`TEAS Stamp: USPTO/BAS-XX.XXX.XX.XXX-2021090216294399
`5189-97009108-78121fd5315fcc0b42e83ef357
`cf6dc1d08a7b4dce22f1b3ed6e85f3d95029774-
`DA-29434497-20210902143555145139
`
` 
`

`

`ORYZA PHARMACEUTICALS INC.
`
`

`

`
`
`

`

`=
`
`9/2/2021
`
`Oryza Pharmaceuticals
`
`PHARMACEUTICALSINC.
`
`ax
`
`CAREERS
`TECHNOLOGY
`)tYZa PRODUCTS&SERVICES
`
`
`
`
`‘Dout Us
`A
`i}
`Be |:
`
`
`illili
`
`
`
`Overview
`
`Oryza Pharmaceuticals,
`
`Inc.
`
`is a privately owned company, with primary research and development
`
`operations based in Coral Springs, Florida, USA. We engage in the development, manufacture, marketing,
`
`distribution and sale of specialty pharmaceutical products primarily in the United States and China. Oryza
`
`is dedicated to developing affordable branded and generic pharmaceutical products of high efficacy,
`
`safety and quality. We also form strategic R&D partnerships with companies in selected product areas.
`
`
`
`oryzapharma.com/about-us.html
`
`1/3
`
`

`

`9/2/2021
`
`Oryza Pharmaceuticals
`
`s
`
`aJt
`
`PRODUCTS&SERVICES
`
`PHARMACEUTICALS INC.
`
`USA
`
`TECHNOLOGY
`
`SHENZHEN
`
`CAREERS
`
`
`
`TECHNOLOGY
`
`For general queries, please contact Coral Springs, Florida
`Ue
`33065
`
`alt ablK-16 alee 1a¢
`High-Tech Industrial Park
`
`4117 NW 124th Avenue
`
`805, Phase 2, Tsinghua
`
`info@oryzapharma.com
`
`USA
`
`(North)
`NanshanDistrict,
`Shenzhen, China 518057
`
`PRODUCTS & SERVICES
`
`oryzapharma.com/about-us.html
`
`3/3
`
`

`

`9/2/2021
`
`Oryza Pharmaceuticals
`
`TECHNOLOGY
`
`CAREERS
`
`a
`
`alx)tYyZa PRODUCTS&SERVICES
`
`ee
`
`PHARMACEUTICALSINC.
`
`Products
`
`Oryza Pharmaceuticals develops, manufactures through CMO and CRO partners, and markets high-quality
`
`and affordable generic pharmaceutical products. We focus on applying our know-how to develop and
`
`manufacture high-end products,
`
`including but not
`
`limited to, extended release, controlled release,
`
`targeted release, and tamper-resistant release for controlled substances.
`
`Services
`
`Weoffer services to clients in areas including:
`
`Utilizing Oryza's innovation technologies and drug delivery
`
`platform to selectively provide contract services in product
`
`development, including ANDA, 505 (b)(2) and FTF products.
`
`oryzapharma.com/products.html
`
`1/3
`
`

`

`9/2/2021
`
`Oryza Pharmaceuticals
`
`VO Y PHARMACEUTICALSINC.
`
`PRODUCTS & SERVICES
`
`TECHNOLOGY
`
`CAREERS
`
`= ENGLISH v
`
`oryzapharma.com/products.html
`
`2/3
`
`

`

`9/2/2021
`
`Oryza Pharmaceuticals
`
`a
`
`QaJtYyZaQ PRODUCTS&SERVICES
`
`PHARMACEUTICALS INC.
`
`TECHNOLOGY
`
`SHENZHEN
`
`CAREERS
`
`
`
`TECHNOLOGY
`
`USA
`
`For general queries, please contact Coral Springs, Florida
`Ue
`33065
`
`alt ablK-16 alee 1a¢
`High-Tech Industrial Park
`
`4117 NW 124th Avenue
`
`805, Phase 2, Tsinghua
`
`info@oryzapharma.com
`
`USA
`
`(North)
`NanshanDistrict,
`Shenzhen, China 518057
`
`ABOUT US
`
`oryzapharma.com/products.html
`
`3/3
`
`